Valuation : Morepen Laboratories Limited

Market Cap 63.54B 665M 573M 543M 492M 923M 927M 6.44B 2.48B 32.32B 2.5B 2.44B 102B P/E 2025
21.8x
P/E 2026 19.5x
Enterprise Value 65.07B 681M 587M 556M 504M 945M 950M 6.6B 2.54B 33.11B 2.56B 2.5B 105B EV / Sales 2025
1.45x
EV / Sales 2026 1.11x
Free-Float
57.31%
Yield 2025
0.42%
Yield 2026 0.59%
1 day+0.69%
1 week-1.24%
Current month+8.25%
1 month+46.31%
3 months+134.86%
6 months+184.96%
Current year+182.32%
1 week 111.25
Extreme 111.25
122.45
1 month 73
Extreme 73
122.45
Current year 33.44
Extreme 33.44
122.45
1 year 33.44
Extreme 33.44
122.45
3 years 31.31
Extreme 31.31
122.45
5 years 23.65
Extreme 23.65
122.45
10 years 7.21
Extreme 7.21
122.45
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2026
Chief Executive Officer 62 01/02/1992
Director of Finance/CFO 59 03/04/2002
Director TitleAgeSince
Chairman 62 01/02/1992
Director/Board Member 58 13/08/2019
Director/Board Member - 22/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.69%-1.24%+116.57%+194.44% 660M
-0.65%-3.79%+47.85%+90.24% 1,001B
-0.29%-4.62%+51.08%+65.41% 642B
+0.83%-1.19%+21.49%+72.54% 451B
-0.38%-3.45%+29.35%+34.09% 340B
-0.09%-14.68%+11.22%+27.14% 263B
-0.43%-3.61%-1.73%+7.95% 247B
-1.34%-15.03%+35.49%+45.45% 207B
-3.44%-8.32%-21.27%-59.20% 197B
-0.75%-4.96%+24.70%+89.11% 180B
Average -0.53%-5.17%+31.47%+56.72% 352.7B
Weighted average by Cap. -0.43%-4.65%+31.34%+56.58%

Financials

2025 2026
Net sales 18.12B 190M 163M 155M 140M 263M 264M 1.84B 707M 9.22B 712M 697M 29.12B 18.06B 189M 163M 154M 140M 262M 264M 1.83B 704M 9.19B 710M 694M 29.03B
Net income 1.18B 12.35M 10.64M 10.08M 9.13M 17.14M 17.22M 120M 46.03M 600M 46.4M 45.38M 1.9B 949M 9.93M 8.56M 8.1M 7.34M 13.78M 13.85M 96.23M 37M 483M 37.3M 36.48M 1.53B
Net Debt -928K -9.71K -8.37K -7.92K -7.18K -13.48K -13.54K -94.12K -36.19K -472K -36.48K -35.68K -1.49M 1.54B 16.1M 13.87M 13.13M 11.9M 22.33M 22.45M 156M 59.98M 782M 60.46M 59.13M 2.47B
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,919
Date Price Change Volume
11/09/26 115.95 +0.69% 972,729
10/09/26 ₹115.15 -1.20% 847,362
09/09/26 ₹116.55 -0.34% 816,939
08/09/26 ₹116.95 -1.43% 1,171,670
07/09/26 ₹118.65 +4.35% 1,401,707
  1. Stock Market
  2. Stocks
  3. MOREPENLAB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!